![Colin Macaulay](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Colin Macaulay
Gründer bei Viron Therapeutics, Inc.
Aktive Positionen von Colin Macaulay
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Viron Therapeutics, Inc.
![]() Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1997 | - |
Gründer | 13.10.2009 | - |
Karriereverlauf von Colin Macaulay
Ausbildung von Colin Macaulay
University of Alberta | Doctorate Degree |
Statistik
International
Kanada | 3 |
Operativ
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Viron Therapeutics, Inc.
![]() Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
- Börse
- Insiders
- Colin Macaulay
- Erfahrung